Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 503 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-fasting Clear all

Conditions: Tobacco Use Disorder
Interventions: Nicotine Prototype Mini lozenge, Nicorette Mini Lozenge; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: metformin HC1 750 mg extended-release tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy
Interventions: ARAVA® 20 mg tablets, Leflunomide 20 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 2
States / cities: Saint Charles, Missouri • Houston, Texas

Conditions: Healthy
Interventions: [¹⁴C]-LY3484356, LY3484356, [¹⁴C]-LY3484356 (IV); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostate Cancer
Interventions: Abiraterone acetate; Drug
Lead sponsor: Cougar Biotechnology, Inc.; Industry
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Peripheral Artery Disease (PAD), Ischemia, Intermittent Claudication
Interventions: Chocolate Touch, Lutonix Drug Coated Balloon; Device
Lead sponsor: TriReme Medical, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 15
States / cities: Gainesville, Florida • Miami Beach, Florida • Atlanta, Georgia + 11 more

Conditions: Neoplasms
Interventions: GSK3326595, Pembrolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • New York, New York + 3 more

Conditions: Pregnancy Preterm, Neonatal Hypoglycemia, Hyperglycemia Drug Induced
Interventions: Maternal glycemic control; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina

Conditions: Health Behavior
Interventions: peer counseling, Feedback report; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Fasting, non fasting; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions: Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer; Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Normal Glucose Metabolism, Hyperlipidemia
Interventions: fasting 12+ hours, Non-fasting; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Advanced Malignancies
Interventions: parsaclisib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Tustin, California • Hialeah, Florida • Orlando, Florida + 1 more

Conditions: Ischemic Stroke
Interventions: Posturography, Walking Speed, Instrumented 7M Timed UP and GO, Fall Event Records, MRI (3T); Diagnostic Test · Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Obesity, Stroke
Interventions: Lifestyle Management Program, Post-stroke Optimization of Walking using Explosive Resistance; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 35 Years to 85 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Epithelial Ovarian Cancer
Interventions: Intermittent Fasting, Neoadjuvant chemotherapy; Behavioral · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Delayed Gastric Emptying, Gastroparesis
Interventions: gastric ultrasound; Diagnostic Test
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hip Fracture
Interventions: Nutrition, PUSH, PULSE; Dietary Supplement · Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years and older
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 4
States / cities: Farmington, Connecticut • Baltimore, Maryland • Lebanon, New Hampshire + 1 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 10 Years to 20 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Charlottesville, Virginia

Conditions: Glaucoma, Primary Open Angle Glaucoma, Glaucoma, Suspect
Interventions: Collection of genetic material; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 1,152 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cancer, Chemotherapy
Interventions: Virtual reality therapy, Questionnaires, Measure heart rate, Cyber sickness measurement; Behavioral · Procedure
Lead sponsor: Cody Stansel; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Impaired Glucose Tolerance
Interventions: Resveratrol, resveratrol /HMB, Placebo treatment; Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy Volunteers
Interventions: ASP1617, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers

Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions

Leflunomide 20 mg Tablets, Non-Fasting

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

The Chocolate Touch Study

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study

Nutrition and Physical Activity Counseling for Nontraditional College Students

Intermittent Fasting on Body Fat and Quality of Life

Human Models of Selective Insulin Resistance: Pancreatic Clamp

Assessment of Non-Fasting vs. Fasting Lipid Measures in Diabetes Patients

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

Post-Stroke Sensory Reweighting on Walking and Balance Outcomes

EMPOWER: Effects of Weight Loss and Exercise Post-stroke

Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

Blood Markers of Early Pancreas Cancer

Using Point-of-Care-Ultrasound (POCUS) to Assess Gastric Contents Among Fasting Pre-operative Patients Taking GLP-1 Agonists.

Improving Community Ambulation After Hip Fracture

Obesity and Pediatric Multiple Sclerosis

Development and Validation of a Model to Predict Fast Progression in Glaucoma

Virtual Reality on Pain, Stress, and Affect in the Infusion Clinic

Resveratrol-Leucine Metabolite Synergy in Pre-diabetes

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect